Can less be more? new study tests smaller lung surgery after immunotherapy

NCT ID NCT07373899

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether a smaller lung surgery after immunotherapy works as well as the standard larger surgery for people with stage II-IIIB non-small cell lung cancer. About 354 patients whose tumors shrank with immunotherapy will choose either a limited or conventional surgery. The goal is to see if the smaller surgery can preserve more lung function without increasing the risk of cancer coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

surgical procedure (limited vs. conventional lung resection)

What this could lead to

If successful, this could show that a smaller surgery after immunotherapy is just as safe and effective, helping patients keep more lung function.

What could go wrong

This is an early-stage, single-center study with only 354 patients. The results may not apply to all lung cancer patients, and there is a risk that limited surgery might not control the cancer as well.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••